20.09.2023 - CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) - Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas . Seite 1